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During the last 150 years or more, society has witnessed many key scientific discoveries and inventions, which have dramatically 
improved not only our quality of life, but our lifespan. However, the motivation of scientists to provide scientific advances has generally 
not been the achievement of these goals, but mainly driven by research curiosity. Fundamental scientific studies, also known as basic 
science, have paved the way to a society of knowledge by means of continuously evolving education systems, and have led to applied 
science and technological breakthroughs changing the World. However, without basic science such life-changing advances would not 
happen, which is poorly understood by the society. Having this in mind, chemists and biochemists working in a chemistry network 
highlight here examples of how basic science has played a crucial role and led to major breakthroughs. In seven short stories, the authors 
describe cases and historical events where basic research discoveries have advanced science, and opened avenues for future achievements. 
Investment in basic science is crucial for a nation’s health and wealth. The support of scientists driven by curiosity ultimately can benefit 
the whole of society, not only in innovative products, but also in the improvement of the understanding of our own lives. 
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INTRODUCTION
Science is knowledge, and scientific research generates new 
knowledge. This new knowledge improves human health and well-
being, in particular health by improving the detection and treatment 
of diseases, the quality of our food, and our interaction with the 
environment. 
The most fundamental scientific knowledge is the basis of what 
we call basic scientific research. Often such research does not set out 
to solve a given problem, but to explore new problems and inspire 
others. It is often many years, even decades or more, before the 
value of basic scientific research is appreciated and recognisable, 
and widely-appreciated applications are generated. 
The financial support of basic scientific investigations is a 
key investment for the future, which generates long-term major 
achievements. However, the value of basic research studies is not 
readily appreciated, neither by lay people, nor even by young students 
of science. Indeed, it is not always evident, even for highly trained 
scientists, that specific basic research will lead to breakthroughs. This 
may be, in part, the reason for the lack of enthusiastic support by 
governments. There is an increased call for the naming of potential 
“beneficiaries” (or a response to the “market”), and scientific agencies 
are even more pressed to show they are financing scientific projects 
that can generate a “useful” end product, very soon or in the near 
future, leading to support being prioritized for applied science. Even 
if this concern is fair, useful applications of basic science usually do 
not emerge without a solid basis from fundamental scientific studies. 
Applied research has a limited lifetime of new ideas, usually with 
only short-term benefits. Novel scientific breakthroughs are critical to 
feed and keep continuously generating future applied benefits. There 
is a well-trodden pathway along which basic science feeds applied 
science and technology. If basic science is not done, then, no major 
applications are likely to arise, just as a river will dry up if it is not 
fed with a source of water (ideas). 
As an example, in 2019, a well-known forum took place in Brazil 
with scientific agencies of 45 Countries (Meeting of the Global 
Research Council), where they discussed the increasing expectation 
of delivering support to research with “societal or economic” impacts, 
and 18 principles were listed for that goal.1 Notably they reiterated a 
previous principle on the dynamic interplay between basic research 
and innovation that “focusing too much on short-term results will put 
the future seeds of innovation at risk”.1 
But what is indeed basic science and why should we (society) 
believe it must be adequately funded? Here we highlight reasons 
why society should invest money in basic investigations and 
emphasise how such investment can pay dividends for the whole 
of society.
It is also the job of scientists to convince sceptics of the value of 
their work, current examples including anti-vaccine and anti-climate 
change groups. Such anti-views are currently held globally in a range 
of countries, with the backing of social media.2-4 All of this, strongly 
supports the view that scientists must give priority to educating people 
at all levels, with increasing effort to communicate to society about 
science, with illustrative cases and facts about scientific knowledge. 
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better explain and advocate the scientific knowledge behind some 
key topics, and alert the society to their risks.5-10 
Here, we tell 7 short stories to exemplify basic science and the 
actual impact it can have (or is expected to have) in our society. 
These randomly-chosen stories are close to the interest and scientific 
endeavors of the authors themselves. The authors have a common 
goal to work in scientific collaboration within a topic of bioinorganic 
chemistry, a field at the frontier of organic/inorganic chemistry, 
biology and medicine. 
It is interesting to note that the authors are scientists from five 
different Countries (Brazil, Portugal, United Kingdom, France and 
Australia) and from three different continents (South America, Europe 
and Australia) sharing their excitement, stories, and views on the 
relevance of basic science, which makes this article a more global 
representation of ideas. What motivates scientists to do basic science 
is curiosity. Financing that may help to uncover what is not in front 
of our eyes, and lead to breakthroughs.
These stories are intended to illustrate how basic science is 
relevant not only to the advancement of our knowledge of Nature, 
but can lead to important contributions to society.
HOW AN ATMOSPHERIC POLLUTANT (NITRIC 
OXIDE, NO) HAS EMERGED AS A KEY BIOLOGICAL 
MOLECULE IN HUMANS: FROM BASIC STUDIES TO 
THE DEVELOPMENT OF NOVEL MEDICINAL AGENTS 
BY LUIZ G. F. LOPES
Cardiovascular diseases (CVD) are the leading cause of death 
worldwide, accounting for nearly 17.9 million people dying in each 
year, making up 32% of all global deaths (WHO).11 This type of 
disease is caused, mainly, by dysregulation of blood pressure like 
arterial hypertension. Blood pressure regulation is controlled by the 
endothelium-dependent relaxation factor (EDRF), which in the 80’s 
was studied by Furchgott, Murad and Ignarro. These researchers 
concluded that EDRF was indeed the nitric oxide molecule, which 
would bind and stimulate the soluble guanylate cyclase enzyme.12 
This discovery yielded the Nobel Prize for Physiology or Medicine 
in 1998 for these researchers.
After all basic studies carried out by these three researcher labs, 
among others, regarding the identity and action of the EDRF in 
endothelium function, it was possible to explain how nitric oxide (NO), 
a diatomic inorganic gas, known until that time as an air pollutant, could 
transmit chemical signals in the human body. Those studies brought 
up a true revolution in medicine, where NO has been involved in many 
key processes, and has an important role in cardiovascular disease 
treatment. Basic understanding of the reactivity of the NO molecule 
became essential to better understand its fate in the body and how to 
use it. In this field, sodium nitroprusside (SNP), Na2[Fe(CN)5NO], an 
iron-based NO donor molecule, has been used clinically to lower blood 
pressure in cardiac surgery, hypertensive crises, heart failure, vascular 
surgery, pediatric surgery, and other acute hemodynamic applications.13 
SNP is indeed a prodrug, which, upon administration into the patient, 
reacts with sulfhydryl groups of biomolecules in the erythrocytes, 
albumin, and other proteins to release NO.14 
The use of SNP is necessary in certain cases when a patient needs 
to quickly lower their blood pressure. This metal-based compound 
was discovered in 1851 by Playfair when he was studying the 
reactions of potassium salts containing cyanoferrates with nitrous 
acid.15 Interestingly, its use in patients was first proposed by Johnson 
in 1922,16 and was used with safety and efficacy to lower the blood 
pressure in severely hypertensive patients in 1955,17 many decades 
before any knowledge of the biological role of NO. However, despite 
the proved efficacy of this prodrug, its use needs to be controlled 
due to toxicity. SNP, in vivo, reacts with oxyhemoglobin to form 
methemoglobin leading to release of NO and cyanide,18,19 a poisonous 
molecule, which can be accumulated in the body making it toxic to 
cerebral endothelial cells,20 hepatocytes,21 and neural cell lines,22 
due to generation of reactive oxygen species inducing cell death by 
apoptosis.13 So, new strategies to overcome cyanide toxicity or new 
non-cyanide-based NO donor compounds needed to be developed. 
However, to reach this goal it is necessary to have a series of basic 
understanding of the properties of a new compound enabling a rational 
design, where its final products are less toxic, rates of NO release are 
adjustable as well as to prepare stable molecules.
Having all of that in mind, our group has been working mainly 
on preparing new non-cyanide-based metallo-nitrosyl species as 
NO (and/or HNO) donors, employing mostly ruthenium and iron 
metal centers. During these years, we have learned from many basic 
studies how to modulate the reactivity and stability of metal complex 
aiming to develop better donors with attractive biological properties. 
Recently, we have also developed a strategy to minimize the cyanide 
release from SNP as well.23
In the first case, we have prepared several nitrosyl metal 
complexes, which can release NO and/or HNO selectively upon 
chemical and/or electrochemical reduction of the [MII-NO+] 
moiety or even by light irradiation. These compounds have shown 
great promise as new candidates of non-cyanide-based NO/HNO 
releasers, and, consequently, we have observed a series of exciting 
biological properties such as vasodilation activity,24 neuroprotection 
during ischemia/reperfusion in the brain,25 anti-Chagas disease,26 
anti-paracoccidioidomycosis activities,27 gastric protection,28 anti-
leishmanial activity,29, 30 anti-angiogenesis activity31 and analgesic 
effects,32 among others.33-36 Some of these compounds have also 
shown low cytotoxicity, exhibiting a high lethal dose in mice,26,34 
stimulating further steps. Beyond our own compounds, many other 
groups in Brazil and around the World have shown the potential of 
NO donors in medicine, where exciting products have advanced such 
as socks for diabetics,37 bandages for organ preservation and wound 
healing among others.38-40
In the second strategy, we recently incorporated sodium 
nitroprusside into silica nanoparticles (MPSi-NP) and evaluated its 
ability to preserve vasodilation properties but decreasing cyanide 
release in biological fluids.23 This new system showed similar 
efficiency in promoting vasodilation compared with free SNP, but 
with a remarkably lower cytotoxicity. Our direct measurements of 
cyanide release supported an expressive decrease in comparison to 
free SNP. So, this seems to be a worthy strategy to further pursue to 
better overcome cyanide toxicity of SNP. All of these achievements 
and future expected products were developed due to our understanding 
of the fundamental properties of these compounds through basic 
research investigation, and more is coming.
150 YEARS OF THE PERIODIC TABLE: THE ELEMENTS 
OF LIFE AND MEDICINES – THE IMPACT OF BASIC 
CHEMICAL RESEARCH ON HUMAN HEALTH BY 
PETER J. SADLER
Nullius in verba (‘Take nobody’s word for it’)
‘Nullius in verba’ is the motto of the Royal Society (of London), 
the UK’s National Academy principally founded by the scientist John 
Wilkins, of which I am a Fellow. It was founded as a learned society in 
1660, and from 1963 onwards became known as ‘The Royal Society 
of London for Improving Natural Knowledge’. Founding Fellows 
included Christopher Wren, the architect of St Paul’s Cathedral, John 
Wilkins, an Anglican clergyman, natural philosopher and author, and 
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Robert Boyle, a pioneer of modern chemistry (Boyle’s Law for gases 
and early notion of “molecule”).41 
Other well-known Fellows include Isaac Newton (1672), Charles 
Darwin (1839), Michael Faraday (1839), Dmitri Mendeleev (1892), 
Albert Einstein (1921), Dorothy Hodgkin (1947), Francis Crick 
(1959), and Stephen Hawking (1974). 
The motto itself stresses the critical importance of scientific 
research - the acquisition of new knowledge: Fellows strive to 
verify all scientific statements by an appeal to facts determined by 
experiment- do not take anyone’s word for them.
The quest for new knowledge can perhaps be no more 
fundamental than establishing which of the 81 stable elements on 
earth are essential for a healthy life. 
Which elements are essential for human life?
Dimitri Mendeleev created the periodic table as we know it 
today in 1869, 151 years ago. He used the information he had 
about the relative atomic weights of the 63 elements known at that 
time to arrange them in a periodic order that reveals similarities in 
their chemical properties, and importantly predicted the existence 
of gallium, germanium, and scandium, elements which were then 
unknown, and technetium which did not exist on earth until 1937. 
Today we have a periodic table of 118 elements. The heaviest stable 
element found on earth is bismuth, atomic number Z = 83, but the lighter 
elements technetium (Z = 43), and promethium (Z = 61) are human-
made, leaving 81 elements which might be essential for our lives. The 
human-made creation of technetium in 1937 has unexpectedly led to 
major medical advances. Its radioactive isotope Tc-99m, a high energy 
gamma radiation emitter with a half-life of 6 hours, is used in over 
10,000 hospitals worldwide to diagnose disease, comprising some 
40 million procedures every year.42 Similarly, compounds of the rare 
earth element gadolinium discovered in 1880, and once thought to be 
only of academic interest, were introduced into the clinic as contrast 
agents in Magnetic Resonance Imaging of the human body in 1983, 
and are now administered to over 30 million patients every year.43
Of the 81 stable elements, there is good evidence that 19 of them 
are essential for human health: H, C, N, O, Na, Mg, P, S, Cl, K, 
Ca, Mn, Fe, Co, Cu, Zn, Se, Mo, and I. Another 7 can be described 
as potentially essential: F, Si, V, Cr, Ni, Br and Sn. In total there 
is documented clinical and medical use of about 76 elements in a 
variety of compounds and other forms. Even radioactive elements 
find widespread use in the detection and treatment of diseases.44-46
I describe here briefly some of the basic research my research 
group and I have carried out recently in collaboration with Brazilian 
scientists: specifically Ana Gondim, Eduardo H. S. Sousa, Luiz 
Gonzaga de França Lopes, Catherine Teles, and Benildo S. Cavada 
from the Federal University of Ceará, Fortaleza, and Carolina 
Oliveira, and Victor Deflon at the Federal University of Uberlândia 
and University of São Paulo, and their colleagues. Visits to my lab in 
the UK have made very important contributions to our discoveries. 
Discovery of new medicines in Brazilian flora 
About 40% of prescription medicines used today are derived 
from plant compounds. These include Artemisinin, an antimalarial 
from the sweet wormwood plant, digitoxin, a cardiotonic (improves 
heart action) from floxgloves, etoposide, an antitumour agent from 
woodland mayapple plants, morphine, an analgesic from poppy seeds, 
quinine, an antimalarial from the bark of the cinchona tree, Taxol, an 
antitumour agent from the the bark of the yew tree, and rifampicin, 
an anti-tubercular drug extracted from a soil bacterium. The first 
mass-produced antibiotic Penicillin, is derived from Penicillium fungi.
Brazil has a rich diversity of plants with enormous potential 
for the discovery of new medicines. My colleagues at the Federal 
University of Ceará have isolated and characterised a lectin protein 
from seeds of the Dioclea lasiocarpa, a flowering plant from the pea 
family, collected from the northeast coast of Brazil.47
Remarkably, we found that Dioclea lasiocarpa lectin protein, 
which contains calcium and manganese metal ions and binds strongly 
to sugar molecules, can kill human ovarian, lung, breast and prostate 
cancer cells at very low (nanomolar) doses.48 Lectins are often 
resistant to digestion and therefore candidates as oral drugs. Further 
research based on these promising initial findings might lead to a new 
anticancer drug with a novel mechanism of action that can combat 
resistance to treatment with current anticancer drugs. 
In collaboration with Jan Balzarini and colleagues (Rega 
Institute for Medical Research, Leuven, Belgium), we further 
investigated the biological activity of 9 lectins extracted and 
purified from Northeastern Brazilian leguminous species and 
algae.49 Notably several of these lectins showed highly potent 
(nanomolar) activity when tested against a panel of 18 different 
viruses, including HIV and influenza viruses. These encouraging 
results suggest that Brazilian flora are a source of novel antiviral 
compounds with therapeutic potential, which might have potential 
for treating COVID-19 as well.
Figure 1. The crest of the Royal Society of London (©The Royal Society) 
bearing the motto ‘Nullius in verba’, together with an extract from the Charter 
Book signed by newly-elected fellows, and examples for Isaac Newton (1672) 
and Charles Darwin (1839). Even today, Fellows sign the book using a quill 
pen and black ink. Currently there are about 1,600 Fellows and Foreign 
Members; 52 Fellows and up to 10 Foreign Members are elected each year. 
Newton discovered the laws of gravity and motion, and invented calculus. 
Darwin’s proposition that all living species have descended from common 
ancestors is now a fundamental scientific concept. After publication of his 
book “On the Origin of Species” in 1859, it took several decades before his 
views on natural selection as the basis of evolution were accepted. The crest 
is reproduced with permission from The Royal Society
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New approaches to cancer treatment
The Nobel Prize in Physiology or Medicine 2019 was awarded 
jointly to William Kaelin, Peter Ratcliffe and Gregg Semenza for their 
discoveries of how cells sense and adapt to oxygen availability, and how 
oxygen levels affect cellular metabolism and physiological function. 
Some of their important discoveries were made over 25 years ago.50
A key protein for oxygen-sensing in our cells is the hypoxia-
inducible factor (HIF). Normal oxygen levels control rapid HIF-1α 
degradation with the help of oxygen-sensitive enzymes (iron-
dependent prolyl hydroxylases which add oxygen atoms to the 
protein). In hypoxia, HIF-1α is protected from degradation and can 
bind to DNA and regulate gene expression.
HIF-1α appears to contribute to the mechanism by which cancer 
cells grow rapidly even under the hypoxic conditions in tumours.51 
HIF-1α is stabilised by nitric oxide (NO), a reactive small molecule 
which promotes dilatation of blood vessels and blood flow. In contrast, 
the protonated form of reduced NO (HNO), which has the same 
number of electrons as O2 (isoelectronic), promotes degradation. 
The ruthenium coordination complex [Ru(bpy)2(SO3)(NO)]+ can 
liberate HNO on reaction with glutathione (which is abundant in 
cancer cells), and has potential as an anti-angiogenesis anticancer 
agent, reducing the growth of new blood vessels which tumours 
need to grow.31 It is interesting to note that ruthenium is ca. 20-fold 
cheaper than platinum, and so its cost is not an economic restraint on 
its use in medicine. Beyond that, in general, ruthenium compounds 
are less toxic than platinum, but this property does not depend only 
on the metal itself, but also on its oxidation state and the surrounding 
ligands. This issue can be illustrated using the example of cisplatin 
(cis-[Pt(NH3)2Cl2]), which is toxic to cancer cells, but its isomer 
transplatin (trans-[Pt(NH3)2Cl2]) is not, while the Pt(II) tetra-ammine 
complex of [Pt(NH3)4]2+ has a very low toxicity. 
There is potential too for medical use of osmium the heaviest 
congener in group 8 (Fe, Ru and Os) of the periodic table. So far, the 
medicinal chemistry of osmium has been little explored. My research 
lab has recently discovered organo-osmium complexes which are 
more potent toward cancer cells than the clinical drug cisplatin.52
Platinum compounds – the most widely used drugs for cancer 
treatment
Platinum compounds are currently used in about 50% of all 
chemotherapy treatments for cancer. The serendipitous discovery of 
the anticancer activity of platinum compounds provides an example 
of how basic research can unexpectedly lead to applications which 
benefit society, in this case curing cancer. The anticancer drug cisplatin 
was unexpectedly discovered in the laboratory of physicist Barnett 
Rosenberg at Michigan State University in the late 1960s, whilst he 
was studying the effects of electric fields on (bacterial) cell division.53 
The passage from an academic laboratory bench to the clinic is slow- it 
took 10 years for platinum, and continued investment of funding during 
such development is essential. From this discovery, second generation 
platinum drugs have followed, carboplatin and oxaliplatin, and others. 
Oxaliplatin was first discovered in 1976, but took over 20 years to reach 
clinical approval, before becoming a billion-dollar drug. 
Now my research group has discovered light-activated platinum 
anticancer drugs with potential for treating resistant cancers with 
reduced side effects.54
Adventures with palladium
Platinum shares similar chemistry with palladium, another 
precious metal which is above it in group 10 of the periodic table. 
Despite the common flat, square-planar shapes of both Pt2+ and Pd2+, 
it is difficult to design active Pd2+ anticancer complexes. They react 
too quickly; they exchange their bound ligands before they reach 
target sites cells. However, we have found that this chemistry can 
be drastically changed by wrapping chelating ligands around Pd2+.
New palladium complexes with thiosemicarbazonate ligands 
derived from pyrene exhibit potent antiproliferative activity against 
human ovarian cancer cells.55 These complexes are potent inhibitors 
of the topoisomerase IB, an enzyme which controls DNA winding/
unwinding, with selectivity for cancer versus normal cells. These 
encouraging data may generate new drugs for combatting resistant 
cancers.
WHEN BASIC RESEARCH CROSSED APPLIED 
RESEARCH: THE CASE OF TAXOL BY VANIA 
BERNARDES-GÉNISSON
As professor of medicinal chemistry at the Faculty of Pharmacy 
of the University Paul Sabatier (Toulouse-France) and a research 
scientist, I have chosen to illustrate, in the following paragraphs, the 
importance of the basic research through an example that has had a 
deep impact both on a societal and personal level. I hope this case will 
help the reader to understand the difference between basic research 
and applied research.
In the 1980s, to build a new road in “Gif sur Yvette” (a French 
commune located twenty-four kilometers south-west of Paris), several 
yew trees were cut down. Quite opportunistically, Dr. Pierre Potier, 
pharmacist and researcher at CNRS (French National Center for 
Scientific Research), decided to collect them to isolate and identify the 
compounds naturally produced by this species.56 For this, of course, 
financial support was needed. In our current politico-scientific context, 
in which governments are drastically reducing investments in basic 
research, one can ask who else would have wished to sponsor this work 
without actually knowing what could be found. Would you be willing 
to invest your money in this project and support the curiosity of this 
French researcher? This classical academic work, held at the “Natural 
Products CNRS Institute” (French public research institution), led to 
the discovery of a novel natural compound that immediately showed 
immense interest in the pharmacological field. Indeed, at the same 
period, Bristol Myers Squib (BMS), an American pharmaceutical 
company, was developing a new antitumor drug, called paclitaxel 
(Taxol®, hereinafter referred as taxol) extracted from the bark of the 
Pacific yew.57 Despite the very promising results obtained with this 
compound during the clinical study phase, its development as a new 
anti-cancer drug was threatened for ecological reasons. Indeed, to 
isolate 25 kg of the new antitumor agent about 38,000 trees would 
have to have been cut down, which would raise alarming environmental 
issues associated to the particularly slow growth of this species.57 In 
addition, taxol exhibits a very complex molecular structure and the total 
synthesis of this product at an industrial laboratory for a world scale 
manufacturing could not be considered. Indeed, the first total syntheses 
of taxol were only reported independently by K. C. Nicolaou58 and R. 
A. Holton59,60 in 1994, more than 20 years after the first isolation of the 
natural product.61 Furthermore, these synthetic routes involved about 40 
steps and had an overall yield well below 1%. So, by lack of material, 
it would not be possible to continue the clinical development of this 
promising antitumor compound and the study would be stopped. It 
was at this point that Dr. Potier’s story crossed that of BMS. Indeed, 
Dr. Potier’s team had found in the thorns of the yews of Gif sur Yvette, 
a new natural product (10-deacetylbaccatin III, Figure 2) with the 
same basic framework as that of the antitumor taxol, studied by BMS, 
although devoid of any significant anticancer activity. A prominent 
potential interest of this compound was that it could be extracted from 
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the renewable thorns without causing death of the tree. In addition, all 
that was missing by comparison to taxol was only a small side chain 
with two stereogenic centers of well-defined configurations. However, 
anchoring of the side chain to the natural basic framework was essential 
for the anticancer activity. It was thanks to previous works carried out by 
notable researchers,62-64 who wanted only to deepen their knowledge in 
fundamental organic chemistry (stereochemistry, asymmetric synthesis, 
protecting groups, total synthesis of natural products) without worrying 
about whether their discoveries would have immediate benefits for the 
society, that the synthesis of this lateral chain respecting the same three-
dimensional structure as that of the natural product and its coupling 
with the natural framework (deacetylbaccatin III) were achieved within 
a suitable time span allowing the clinical development of taxol. 
This is an interesting case, where without the basic research on 
organic synthesis, the preparation of taxol and even that of its cousin 
docetaxel (Taxotere® developed by Rhône Poulenc, hereinafter 
referred as taxotere, Figure 2)65 which is in fact a chemical precursor 
of taxol serendipitously discovered by the Potier’s team, would not 
have been possible and many women around the world, including 
myself, could not have benefited from these drugs in breast cancer 
treatment.
The taxol story is so just one of the cases one can choose to 
illustrate the importance of fundamental research in the discovery of 
new drugs. In fact, a large number of drugs have been discovered “by 
chance” thanks to the curiosity and interest of researchers in basic 
disciplines such as for example the microbiology, organic chemistry 
and others.66
Currently, I am developing research focused on the understanding 
of the activation mechanism of anti-tuberculosis prodrugs like: 
isoniazid,67,68 pyrazinamide69 and ethionamide.70,71 These drugs, 
although known and used in clinics for more than sixty years, still 
hide certain secrets related to their active metabolites, their mode of 
action and their toxicity. Thanks to fundamental research, we hope 
that better knowledge of the behavior of these molecules will be able 
to provide key elements allowing, in the future, the design and the 
synthesis of anti-tuberculosis agents more effective, safer and active 
on wild and resistant Mycobacterium tuberculosis strains to prevent 
the resurgence of tuberculosis worldwide. 
FROM BASIC TO APPLIED RESEARCH, FROM 
BACTERIA TO HUMANS BY JOSÉ J. G. MOURA
Our research group has worked for several years on fundamental 
studies on the role of metal ions in biology, in order to reveal 
structural-function relations in proteins and enzymes involved in 
crucial pathways covering areas such as energy, health, agriculture 
and the environment. Here, we tell a story of one of these cases. This 
all starts in the 1970s and is a good example of how basic research 
may have impact in an applied context. In those days, we detected a 
“strange red protein band” in the chromatographic purification steps 
of a bacterial extract obtained from the biomass of a sulfate reducing 
bacterium, Desulfovibrio gigas (Dg) (a bacterium with impact in 
environmental problems (accumulation of sulfide) and energetic 
interests (hydrogen production and association with methanogens)).72 
The isolated protein was shown after biochemical/chemical methods 
and spectroscopic tools to contain molybdenum (Mo), to our big 
surprise.73
Molybdenum-containing enzymes play a major role in biological 
systems and have been found in two distinct forms: a complex 
[Fe-Mo-S] metallic cluster, which occurs in nitrogenases (a primordial 
enzyme in the N-cycle involved in nitrogen fixation to ammonia), 
and a mononuclear Mo (or W) atom associated with one or two 
pyranopterin-ene-1,2-dithiolate cofactors [Mocofactor or Moco], 
as in Xanthine oxidase, Aldehyde oxidase and Sulfite oxidase.74-77
Extraction of the metal co-factor and the presence of Fe/S centers 
showed that the isolated red protein had unexpected analogies with 
xanthine oxidase a relevant enzyme in human metabolism of purines, 
and related with health problems (i.e., gout disease). Then, we could 
show that this bacterial protein had an aldehyde oxidase activity, and 
reactivity to similar substrates as xanthine oxidase (these group of 
enzymes are quite promiscuous in terms of metabolites accepted).78,79 
The lack of 3D structures of this group of enzymes (the so-called 
mononuclear Mo-enzymes) limited the proposal of mechanisms. In 
1995, the structure of the first mononuclear Mo-enzyme (Dg Aldehyde 
oxido-reductase) was solved and structural details of the active site 
reported.80,81 The ligands around the metal were firmly determined 
and a water molecule in the vicinity of the metal site identified as 
the one involved in O atom insertion in the substrate (conversion of 
aldehyde to carboxylic acid). Inhibitors of this activity were also 
studied identifying the Mo-site as a target of drugs. Then, the bacterial 
structure was used extensively as a model until the structure of the 
human enzyme (Xanthine oxidase) was finally solved in 2000.82
Structural features of Dg Aldehyde oxido-reductase80,81
The aldehyde oxido-reductase Desulfovibrio gigas is a member 
of the xanthine oxidase protein family, as mentioned before, and its 
3D structure has been analyzed at high resolution, a relevant step for 
the understanding of mechanistic aspects (substrate and inhibitors 
interactions). The protein, a homodimer, catalyzes the oxidation of 
aldehydes to carboxylic acids. This protein has structural similarities 
to xanthine oxidase, contains (2Fe-2S) centers, lacking the domain 
that contains a flavin moiety, although it was recognized that a small 
flavodoxin participates in electron transfer (Figure 3). 
The protein molecule is folded into four domains (the first two 
bind the iron sulfur clusters and the others the Moco). The Mo-site 
is deeply buried in the protein accessible through defined tunnel. 
The molybdenum is penta-coordinated with two dithiolene sulfur 
atoms of one molybdopterin (cofactor identified as pyronopterin 
cytosine dinucleotide)73,74 and three oxygen ligands, of which one is 
presumably an oxo or one a sulfide group in the functional sulfo-form 
of the enzyme in analogy to xanthine oxidase. 
Different EPR (X-band) molybdenum(V) were detected for 
Dg Aldehyde oxido-reductase with similarities to the inactive, and 
Figure 2. Structures of the natural products taxol and 10-deacetylbaccatin III and of the non-natural compound taxotere
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the physiologically significant signals develop within the enzyme 
turnover time scale (active forms) of Xanthine oxidase. These 
studies were complemented by CD measurements and advanced EPR 
spectroscopic studies revealing the presence of two types of [2Fe-2S] 
cores, named Fe/S I and Fe/S II centers. 57Fe-enriched Dg Aldehyde 
oxido-reductase enabled iron-sulfur-center site specific labeling, 
enhanced sensitivity for Mossbauer studies (an advantage of using 
bacteria with respect to mammalian systems).77
Mechanism based structure
The 3D structure of the Xanthine oxidase-related molybdenum-iron 
protein Aldehyde oxido-reductase isolated from Desulfovibrio gigas 
was analyzed in its desulfo-, sulfo-, oxidized, reduced, and alcohol-
bound forms at different resolutions. Bound inhibitory isopropanol in 
the inner compartment of the substrate-binding tunnel is a model for 
the reaction with aldehydes, and mechanistic details were proposed 
for the reaction, as well as modes of action of inhibitors (details of the 
proposed mechanism are indicated in the legend of Figure 3). 
Aldehyde oxido-reductase activity has also been found in different 
sulfate reducing organisms. We also obtained complete biochemical, 
enzymatic and structural data for the Aldehyde oxido-reductase 
isolated from D. desulfuricans ATCC 27774, a sulfate reducer that 
can use nitrate as an alternative respiratory substrate to sulfate.83,84 
Relevance of a Bacterial enzyme to Human Heath: implications of 
fundamental research in applied research (i.e., human health)85-90
The lack of fine structural information on the mononuclear 
molybdenum-containing enzymes hampered the detailed 
understanding of the mechanisms operating in these enzymes. 
Investigation of the mechanism of molybdenum containing enzymes 
was considerably enhanced by the crystallographic determination 
of high-resolution 3D structure of the Dg aldehyde oxido-reductase 
(in 1995).80 The enzyme, belonging to the xanthine oxidase family, 
was a potential model for the mechanistic studies on this group of 
enzymes. Almost simultaneously, after the determination of the first 
3-D structure of Dg aldehyde oxido-reductase, followed in 1996, 
the structural determination of Rhodobacter sphaeroides DMSO 
reductase, that allowed a direct comparison between molybdo- and 
tungsto-enzymes and showed how these apparently disparate enzymes 
are surprisingly related. 
Molybdenum (together with Tungsten) is the heaviest element 
(metal) used by biology and plays relevant physiological roles in 
humans, with only four molybdoenzyme types: Xanthine oxidase, 
Aldehyde oxidase, Sulfite oxidase and Mitochondrial Amidoxime-
reducing component. One of the molybdenum-dependent metabolic 
processes is purine catabolism. Xanthine oxidase is responsible for 
catalyzing the sequential hydroxylation of hypoxanthine, in general, 
producing urate, which, in humans, is the terminal product of purine 
catabolism. A high concentration of urate in the blood is a risk factor 
for gout deposition of monosodium urate crystals in and around the 
joints and the development of many other diseases (i.e. inflammatory 
arthritis). Major risk factors for gout include hyperuricaemia, genetics, 
dietary factors, and others. It is reported prevalence of gout worldwide 
ranges from 0.1% to approximately 10%, and the incidence from 0.3 
to 6 cases per 1,000 person-years.91 
Different strategies, including increasing excretion and/or 
decreasing the formation of urate by inhibiting xanthine oxidase 
have been applied. For this reason, human xanthine oxidase is one 
of the targets of therapies against hyperuricemia and gout. The full 
characterization of Dg Aldehyde oxido-reductase (biochemical and 
Figure 3. A) Xanthine oxidase (in right) contains four redox centers: Moco (the pterin cofactor is a molybdopterin cytosine dinucleotide), two (2Fe-2S) centers 
and a FAD moiety, while aldehyde oxido-reductase (in left) has strong analogies with Xanthine oxidase and the polypeptide chain folds into four domains: 
two bind the iron sulfur clusters and the others are associated with Moco. The additional domain (in green), that binds FAD in xanthine oxidase, is absent in 
Dg Aldehyde oxido-reductase (does not contain a flavin moiety), although it was recognized that a small flavodoxin participates in electron transfer instead. 
B) shows a proposed mechanism for the conversion of aldehydes in carboxylic acids based on Dg Aldehyde oxido-reductase structural studies (see text)76,94,95
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first structural data) was a fundamental achievement during the period 
of lack of information on the related human enzymes (Xanthine 
oxidase and Aldehyde oxidase) enabling the proposal of mechanisms 
and inhibitory sites to be studied, for drug development.
A quite new aspect is the participation of molybdenum enzymes 
that are involved in a wide range of metabolic pathways may also 
utilize nitrite to the production of NO, a powerful signaling molecule, 
under anoxia. So, molybdenum enzymes have been described as “non 
dedicated” nitrite reductases, providing a mechanistic pathways for 
O atom abstraction, in alternative to O atom insertion, as depicted 
in the conversion of aldehydes to carboxylic acids, for example.92,93 
These new discoveries might open pharmacological opportunities to 
modulate NO response under hypoxic conditions.
BASIC RESEARCH, A BASIC HUMAN NEED BY REMI 
CHAUVIN
The question of the usefulness or profitability of basic research 
(BR) is legitimate: BR has indeed a cost, which, beside private 
supports, must be mainly provided by public funding. According to the 
most recent OECD report for 44 countries,96 public BR expenditure 
corresponds to ca 0.4 ± 0.3 % of GDP, while the total public 
expenditure on Research and Development (R&D) to ca 0.6 ± 0.3% of 
GDP. Within R&D, the place of BR here deserves a special attention 
as opposed to applied research (AR), which is for its own part widely 
funded by the enterprise sector. The AR-BR dialectic is addressed 
below through (i) the societal context and (ii) selected illustrations 
of passages from BR discoveries to AR developments.
The AR-BR dialectic: societal context
What is basic research? Summarizing a current opinion, it might 
be quickly defined as an effort aiming at discoveries that could be 
appraised by very few people only, without prospect of short term 
application that could help in our daily life, for concrete comfort - 
from health to gadget facilities - or abstract enjoyment - from art and 
knowledge to sport. 
While concrete comfort should precisely result from AR taking 
over from BR, abstract enjoyment may refer to the enthusiasm of 
our ancestors, who started building cathedrals, knowing that they 
will never see their achievement. More than beauty, prospect of 
beauty inspired a collective force similar to that of the BR actors 
today. Just as art or sport through the construction cathedrals or 
stadiums, knowledge is a source of enjoyment through education. 
As knowledge continuously relies on BR outcomes, this view should 
make authorities more comfortable when funding BR for the sake of 
education, i.e. people’s welfare.
Selected stories: from BR discoveries to AR development
The essence of BR is not to solve given problems and wait 
for others, but to explore new problems and inspire others, while 
remaining ready for serendipity and prospects of concrete applications. 
The process can be self-consistent, as tentatively illustrated below.
Plenty of examples can be found showing the possibility 
of unexpected practical aftermath of BR results, that could not 
have resulted from on-project programs of standard AR, even by 
serendipity: electricity was not invented by trying to improve the 
candle, a claim often attributed to Niels Bohr.97-99 
In Niels Bohr’s research field, by the way, i. e. quantum theory, a 
remarkable example in the sub-field of quantum chemistry is the basic 
Hohenberg-Kohn theorem (stating that the ground state energy of an 
electron system in a given external potential is uniquely determined 
through a functional of the electron density map).100 This opened the 
way to the Kohn-Sham equations of DFT computation,101 today widely 
used to calculate real molecular structures (instead of simplified 
models thereof) with high reliability and CPU time economy, both 
in BR labs and AR industrial centers. 
In the parent context of quantum mechanics, the advent of 
quantum computers has just allowed a given computation to be 
performed in 200 seconds, instead of 10,000 years by the fastest 
classical computer.102 In 2019, this proof of concept of “Quantum 
Supremacy” opened “a new era in the computing industry”, Prof. 
Robert Young said.103 This appears as a dialectic achievement, 90 years 
later of Paul Dirac’s introductory statement of his seminal paper on 
Quantum mechanics of many-electron systems:104 “The underlying 
physical laws necessary for the mathematical theory of a large part of 
physics and the whole of chemistry are thus completely known, and 
the difficulty is only that the exact application of these laws leads to 
equations much too complicated to be soluble. It therefore becomes 
desirable that approximate practical methods of applying quantum 
mechanics should be developed, which can lead to an explanation 
of the main features of complex atomic systems without too much 
computation”.
In the field of experimental chemistry, numerous discoveries 
could serve as pleadings for BR. Far from any medicinal application, 
early basic research concerns on chiral phosphorus compounds and 
asymmetric catalysis is eloquent: the findings of the efficiency of the 
DIOP ligand in enantioselective rhodium-catalyzed hydrogenation 
of dehydro-aminoacids,105 parallelized the way to the MONSANTO 
process for the industrial production of L-DOPA, the main prescribed 
drug against the Parkinson’s disease.106 This illustrates of the AR-BR 
research complementarity for addressing challenges common to 
industrial and academic concerns.
In the backdrop of homogeneous catalysis, ligand design and 
coordination chemistry stand as more fundamental BR concerns, whose 
spinoffs are less patentable but can provide guidelines for applications, 
as for instance proposed by our “C-rich/P-poor polar ligands” 
typology.107-109 Other personal experiences are developed below.
At the frontier between conceptual and experimental chemistry, 
the basic issue of expanding the size of a molecule with a minimal 
change of its other characteristics led to our proposition, in 1995, of 
the notion of carbo-mer (see Scheme 1), along with first attempt at 
synthesis of carbo-benzene representatives.110 As ab initio ideas do not 
exist, it must be mentioned that the same kind of concern can be found 
implicitly addressed, albeit in a less general form, in previous reports 
on particular molecules.111,112 After 15 years of basic computational 
and experimental investigations of these “funny molecules”113 - Art 
for Art’s sake, a few colleagues said -, properties bearing concrete 
prospects of applications started to appear (e.g. electrical, optical, 
liquid crystal properties),114 prevailing today with patent deposits 
(e.g. on sustainable hydrogen energy).115
Actually, the concept of carbo-mer is so basic that it is simple, 
and it could have been proposed decades before 1995. Surprisingly, 
however, it was simultaneously proposed in the specific case of the 
benzene molecule exactly at the same time (the same month of the 
same year in the same volume of the same journal) by Japanese and 
French authors, seemingly in an independent manner.110,116 Although 
it might just be incidental, one may also envisage that the idea was 
“floating in the air” in a subliminal manner through the common 
literature registry unifying International BR connections across the 
world. Several examples of such coincidences have been reported. 
For the sake of financial competition, such a connection is of course 
much weaker in industrial R&D. The literature supports of the BR 
community and AR community have actually very different editorial 
spirits: while the former communicates through publications based 
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on a peer-review evaluation process, the latter communicates through 
patents tending to present results in a legally minimal manner, 
sometime misleading on purpose.
As mentioned above, BR is essentially intended to be inspiring, 
and, for consistency, at first within the context of BR itself. This 
is what happened in 2003, as we wondered about the stability of 
carbo-benzene precursor in the flask. In the flask first, but why not in 
Nature?117, 118 Inspection of the literature showed that a few molecules 
with similar structural features were indeed extracted from vegetal 
roots or animal organisms, such as carrots or marine sponges.119-125 
As expected from their functionality foreshadowing reactivity, 
natural metabolites were described to exhibit biological properties, 
such as moderate anti-tumor activity. Nonetheless, the intriguing 
relative stability of such molecules in the biological medium of their 
hosts, prompted us and collaborators to play with their structure by 
superseding Nature in making artificial analogues. Entry on stage of 
synthetic chemistry led to bio-inspired targets, which, after isolation, 
turned out to exhibit up to 670 times the activity of their natural 
congeners against cancer cells.126 The molecules’ targets in the cancer 
cells were then studied in a systematic manner by biologists, who 
evidenced an unprecedented mode of action.127 
Today, a patent is underway while preclinical tests against 
particular virulent cancer cells are being undertaken. At the time of 
writing, the particular cancer must remain confidential until patent 
deposit,127 thus illustrating further the practical AR/BR research 
relationship. Fifteen years ago, the innocent wonder of basic 
chemists was far from imagining such an outcome of their basic 
questioning, all the more they were not identified by their peers 
in the category of medicinal chemists. Nevertheless, an intense 
cooperation at the basic research level with talented chemists in 
the field, and then with biologists, proved to be invaluable on the 
way to the application.
MOLECULAR INSIGHT TO ORGANIC CATALYSIS BY 
PAUL BERNHARDT
The total synthesis of biologically active natural products has 
led to worldwide deployment of otherwise inaccessible drugs with 
high activity against life threatening illnesses such as cancers, viruses 
and bacterial infections. Given the typical complexity of compounds 
with drug-like properties, bearing a variety of functional groups and 
alternative stereochemistry, selectivity in each synthetic step must be 
ensured for the target compound to be produced in a practical (and 
economically viable) yield. This requires catalysts that enable the 
selective reaction of functional groups to give desired compounds 
without indiscriminately affecting other sites on the molecule. In 
some ways, the catalyst may be seen as a magic ‘black box’ where 
reactants go in and the desired product comes out. If it works then 
everyone is happy and there may be little interest in understanding 
what happens ‘inside the box’; in other words what is the mechanism? 
In 1987 Ley and Griffith reported128 a new generally applicable 
way to selectively oxidise a primary alcohol to an aldehyde avoiding 
over-oxidation to the carboxylic acid or breaking C-C bonds which 
can occur when alternative oxidants are used. The simple ruthenium 
catalyst (tetra-n-propylammonium perruthenate, NPr4[RuO4] or 
TPAP, Scheme 2) has many desirable features including mild reaction 
conditions (high activity) and tolerance to other reactive groups 
(selectivity). In fact, the high demand for the catalyst TPAP led to 
it being made commercially available and it remains the reagent 
of choice for many reactions of this type.129 There are innumerable 
examples of the use of TPAP in organic synthesis, but one notable 
mention is its utilisation (three times) in the classic multi-step total 
synthesis of the drug taxol130 (Scheme 3). 
In spite of its obvious effectiveness, little was known about 
the way TPAP actually worked (it remained a ‘black box’). This 
Scheme 1. Basic definition and examples of the notion of carbo-mer
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included how it was regenerated during the reaction by its co-
oxidant N-methylmorpholine N-oxide (NMO) (Scheme 2). Our 
investigations were primarily aimed at gaining an understanding at 
the molecular level of how this reaction proceeded; curiosity driven 
research without an obvious end point or outcome. The driving force 
was to provide insight for the synthetic community on a popular 
but little understood reaction. Our initial studies showed that the 
alcohol oxidation reaction generated a highly reactive and unstable 
RuV complex which was rapidly reoxidised by NMO to recover the 
RuVII TPAP catalyst and sustain catalysis.131 However, further work 
revealed a more complicated picture.
In a catalytic (zero order) reaction a characteristic feature is 
that the rate of product formation is both rapid and constant over 
time and the reaction finishes when all reagents are used up. In the 
case of the TPAP-catalysed alcohol oxidation (Figure 4A), we were 
surprised to find132 that the reaction rate initially proceeded through 
a ‘slow phase’ but then unexpectedly accelerated to a ‘rapid phase’ 
before finishing when all alcohol had been oxidised to the product 
benzophenone.
Our study revealed much about the way this reaction works on 
the molecular level. However, the most surprising finding was that 
the reaction proceeds ‘normally’, without the slow phase (Figure 4B) 
if impure, commercially available TPAP (contaminated with ~3% 
RuO2) is used. Indeed, most organic synthesis had been carried out 
with commercially available TPAP, so the (undesirable) slow phase 
had remained concealed over the 30-year use of the Ley-Griffith 
oxidation. An ironic discovery that goes against conventional wisdom 
that your reagents should be as pure as possible. If pure catalyst is 
used (Fig. 4, top - TPAP1, light yellow solution) then the abnormal 
behaviour in Figure 4A was seen. Commercially available TPAP 
catalyst (Fig. 4 top - TPAP2, dark brown solution) is only 97% pure 
and the 3% impurity of insoluble RuO2 acts as a solid support on 
which the reaction proceeds more quickly. 
This was basic research aimed at gaining a deeper insight into 
a popular reaction used by organic chemists worldwide. There was 
no intention to find a better catalyst than TPAP, it was merely the 
pursuit of knowledge utilising the collective skills of the collaborators 
from different areas (multi-disciplinary research). However, these 
outcomes will have implications for the way that this catalyst is used 
and stored into the future.
METALS, DRUGS, CYANIDE AND TUBERCULOSIS – 
UNEXPECTED COMBINATION OF INSPIRATIONS BY 
EDUARDO SOUSA
During the 1990s, I had the first opportunity as an undergraduate 
student to work in a research lab doing basic science in Chemistry. 
I was awarded a studentship from CNPq (a major Brazilian agency 
financing science), a very important financial support to engage young 
students in science. At that time I remember reading an exciting 
review about metals in medicine,133 which was an inspiration and 
motivated some of my early interests. However, much earlier, during 
the 1960s, the scientific community had already witnessed a major 
breakthrough in the use of metals in medicine. Considered mostly 
as toxic products, metal derivatives were not much seen as potential 
Scheme 2. The Ley-Griffith Oxidation Reaction
Scheme 3. One step in the total synthesis of taxol
Figure 4. (A) TPAP/NMO oxidation of Ph2CHOH to Ph2CO with pure TPAP (TPAP1, light yellow) showing initial slow phase; (B) the same reaction with commer-
cially available (97% pure) TPAP (TPAP2, dark brown) contaminated with RuO2. Reproduced from Ref. 128 with permission from the Royal Society of Chemistry
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medicines at all. Then, Dr Barnett Rosenberg at the Michigan State 
University (USA) changed everything.134 He was studying how 
electric fields might affect cell division, and for that investigation 
he built an equipment to apply electric current. His hypothesis was 
that electric fields could locally perturb spindle formation during 
cell division. The first organism used in that study was a bacterium 
(Escherichia coli found in our intestine). It might be educational to ask 
if anyone would consider that work to be of any relevance to everyday 
life and worthy investigation. Why support a study on a “harmless” 
gut bacterium placed in an electric field at all? This is a typical case of 
basic research investigation, where “not much” was indeed expected, 
no product foreseen or major advance in knowledge follow, but such 
curiosity motivates scientists to search for new discoveries. 
Remarkably, that study led to the development of one of the most 
important anticancer drugs ever produced, cisplatin ([Pt(NH3)2Cl2]) 
(also briefly mentioned in the stories told by Peter Sadler, section 2). 
Indeed, at the beginning Rosenberg did not know anything about 
this platinum compound, or even from where it would come.135 
During his studies applying electric fields to the bacteria, he noticed 
an abnormal elongation of the cells (ca. 300-fold longer than 
normal- filamentous growth) due to the lack of cell division.135 His 
thinking was that something was disrupting bacterial cell division 
and it might be useful to stop cancer propagation, where cells 
divide very fast. A hint from a chemist colleague about Pt reactivity 
made Rosenberg realize that the applied electric current was indeed 
oxidizing his electrode made of platinum metal (considered a quite 
inert material!).136 During application of an electric potential, in the 
presence of the cell medium, containing oxygen and NH4Cl, minor 
amounts of a platinum compound were produced and eventually 
caused the observed growth effects on the bacteria. So, a search for 
platinum compounds which might be responsible for that took place. 
Later on, they tested a few platinum compounds as candidates for 
promoting that phenomenon, and identified cisplatin ([Pt(NH3)Cl2]) 
as a compound that can not only cause filamentous growth of bacteria 
but also kill cancer cell at very low doses. Interestingly, cisplatin 
had been prepared over a century before that (1844 by Michele 
Peyrone),137 but nobody knew it could be useful. Rosenberg decided 
to investigate its effect against a series of cancer cells and found out 
remarkable activity. Despite initial reluctance, the National Cancer 
Institute (USA) tested his compound and suggested he should apply 
for a grant with them, which was approved.135 From there, outstanding 
results were achieved,138 proving cisplatin was indeed a remarkable 
anticancer drug, leading to its clinical use in 1978 (Platinol®, Bristol-
Myers Squibb). This very successful compound made possible the 
application of platinum in medicine, exhibiting a wide range of use 
in cancers, including lung, ovarian, bladder, testicular, head and neck, 
esophageal, colon, gastric, breast, melanoma, and prostate cancer. 
Since the introduction of cisplatin, for example, testicular cancer 
patients now have a remarkable cure rate of over 95%.139 Around 
the globe, six platinum-based compounds have been approved for 
clinical use.140 Currently, the global market sales are over 1 billion 
US dollars per year, and many other transition metal compounds hold 
promise for future development.141 The success of this serendipitous 
discovery will motivate future generations of chemists, and highlights 
the importance of fundamental basic scientific studies for producing 
life-changing applications for all society. Scientists cannot foresee 
such applications with any certainty. They study what motivates them, 
based on their curiosity. Importantly they must be well trained and 
funded in order to explore, to see and unfold such a breakthrough as 
Rosenberg and his team achieved.
In another short story of basic science, I would mention a 
work developed in our lab starting with a synthesis of a new metal 
compound containing an organic ligand called thionicotinamide 
(similar to vitamin B3). The goal was to investigate the changes 
promoted by that ligand upon binding to the iron complex, in 
comparison to other analogous organic ligands, previously studied 
(e.g. nicotinamide, isonicotinamide, etc). This new compound 
would help us to understand and compare the effects that “minor” 
structural changes could cause on the new metal compound. So, we 
wish to measure the influence of that organic ligand in the color of 
the compound (changes in the orbital energies), its redox potential 
and eventually investigate electron transfer reactions. 
The model iron compound that we were going to use in those 
studies was the sodium amminepentacyanoferrate(II), a complex 
that contained one ammonia (NH3) and five cyanides (CN-) bound 
to iron(II); luckily those cyanides are tightly bound to the iron ion. 
Then, we would make a reaction where ammonia is replaced by 
thionicotinamide. Indeed, starting a project using a complex of iron 
containing those species would sound strange to a naïve student, and 
certainly much more for lay people. Why someone would be interested 
to work with something containing five cyanides, a well-known 
poison,142 and also ammonia, an irritating strong smelling base? But 
again, that was basic science, many times its impact is not immediately 
evident as previously discussed. Indeed, since 1970s, nitroprusside has 
been used as a drug in cases of hypertension emergency143 (another 
detailed story told by Luiz Lopes here, see section 1), where it contains 
five cyanides and one NO molecules, all of them bound to iron(II) 
(Figure 5). Another analogue drug containing six cyanides bound 
to iron(II) is also in clinical used as an antidote for poisoning by 
radioactive cesium-237 and thallium (radiogardase, FDA approved 
in 2003). These cases are a hint to avoid believing you know before 
knowing for sure.
Nonetheless, our basic study was carried out and we were able 
to prepare and isolate two new compounds of cyanoferrate with 
thionicotinamide, supposedly bound to iron(II) and another to iron(III) 
(Figure 5). Unfortunately (or fortunately), the cyanoferrate(III) 
complex with thionicotinamide showed spectroscopic (UV-vis, 
FTIR, RMN, Mossbauer) and chromatographic evidences of another 
compound containing cyanoferrate(II) and 4-cyanopyridine, instead 
of thionicotinamide. That result indicated a redox process happened 
likely promoted by iron(III) oxidizing thionicotinamide, which was not 
expected at that point.144 A literature search showed thionicotinamide 
had some interesting analogues with anti-tuberculosis drugs, called 
ethionamide and isoniazid. This latter is indeed one of the most 
efficient first-line anti-tuberculosis drug in use, but it has faced major 
issue with the development of resistance.145 Those drugs are indeed 
pro-drugs, meaning they could not cure tuberculosis unless they are 
converted (activated) to active species. Interestingly, the process of 
activation of those pro-drugs is carried out through a redox reaction, 
but they need to be mediated by enzymes only found within M. 
tuberculosis. All this history came to us as an inspiration to use basic 
science to work forward. 
Then, we thought that if we prepare a cyanoferrate(II) complex 
containing isoniazid (Figure 5), which is stable as such, we might be 
able to activate isoniazid more easily without using enzymes. If we 
could do that, we might kill even isoniazid-resistant bacteria. Why 
did we think that was possible ? Because we knew from previous 
basic studies that iron(II) oxidation in those complexes was easier 
and faster to accomplish. Then, a series of studies were done to 
show that fast oxidation of iron(II) could be achieved, which would 
accelerate isoniazid oxidation and formation of active species without 
using mycobacterial enzymes.144,146-148 At the same time, outstanding 
collaborators helped us to investigate the potential biological action 
of that compound, called IQG607, and also of other analogues,145, 
149 against Mtb, where great activity was found along with exciting 
pharmacological properties.148, 150-156 Tuberculosis still kills over 
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1 million of people per year around the globe and there is a huge 
necessity for new antibiotic agents to protect the human race from 
stronger and drug resistant pathogens. Our history stands on basic 
science and the interest to better understand nature, which has led 
us to propose new strategies to tackle tuberculosis. More recently, 
we found out that the biological mechanism of IQG607 may not be 
through the original idea of a redox-mediated activation.156,157 Not 
always Nature works as we desire. Nevertheless, this compound 
is well advanced in pre-clinical trials studies150,151,158,159 and bears 
a good chance to move forward. Indeed, IQG607 seems a better 
option than isoniazid particularly when used in combination with 
rifampicin and pyrazinamide, which might even shorthen the length 
of TB treatment.159 Besides that, all these studies provided a basis 
for our lab to mature and design a series of novel metal complexes 
with potential medical applications.
FINAL CONSIDERATIONS
The above-reported stories provide a few examples within 
our own research fields at the intersection of Chemistry, Physics, 
Biology and Medicine, illustrating what basic science is and how 
it can improve our lives, or has the potential to. Basic science and 
applied science are intimately connected - without basic science there 
would not be applications, at least not game-changing applications. 
This situation should be reflected in funding - as a continuum. At 
first sight applied science might appear more attractive than basic 
research from the standpoint of short-term profitability, but it has 
been shown that basic research plays a major role in initiating and 
strengthening applied research.
Scientific research, which advances knowledge of this world we 
live in, is exciting, not only for young people, but throughout life. 
New research is vital - all existing theories and hypotheses need to 
be tested and reinvestigated- never believe what anyone tells you - 
‘Nullius in verba’. 
Academic freedom to pursue fundamental research within a 
University environment without an immediate application should 
be always nourished. Ultimately, the scientific community will 
evaluate the quality/originality of the research work through peer 
review and decide whether the work is important enough to warrant 
publication. Then, only History will define the true impact and value 
of the reported results.
Proper funding for scientific research is an investment not only 
in the lives of young people and the more senior scientists who train 
them, but also in the future health and well-being of all society. 
Curiosity-driven basic research is essentially creative, opening the 
way to further developments. It challenges highly motivated brilliant 
minds, without which, neither the progress nor the innovation could be 
possible. This key issue should not be forgotten by governments and 
also by lay people. Definitely, if a Country wants to be a leading edge 
in innovation and development in the future, there is no alternative 
but to invest wisely in basic research free from the requirements of 
short-term return on investment expectations. 
As we mentioned here, basic research is the core of science and 
many exciting questions crossing even more a multidisciplinary 
frontier deserve funding and hold major potential outcomes. Despite 
many advances in our understanding (and use) of metals in biology, 
for example, we still face an extensive number of unknown answers, 
requiring to be addressed within an interdisciplinary network. For 
instance, the use of CRISPR (gene editing technology) can open 
even more opportunities to precisely modify genes in more complex 
organisms allowing us to better investigate the role of metal sites, 
metal transporters, metal chaperones, eventually allowing a more 
rational creation of artificial systems to deal with our current problems 
(e.g. oil degradation, new fuel/biomass production). The use of (bio)
analytical tools (non-invasive in whole animals as well) may help us 
to answer complex questions relating to the fate and function of native 
and non-native metal complexes, for example, through a (epi)genomic, 
transcriptomic, (metallo)proteomic and metabolomic combined 
approach. Nanotechnology and advanced analytical tools amongst 
other topics can make important contributions in this field, calling for 
broad scientific networks. What and how non-metal-based drugs disturb 
metallomics is poorly known, but still need to be explored. Once we 
advance our fundamental understanding on how metals are handled in 
biology, and even which ones are truly needed (still a current question 
for some elements), then we can more rationally use them in medical 
applications and to improve our well-being, opening, then, new routes 
for innovation and discovery. It is remarkable how much we are now 
learning about the key role of metals in biology, but at the same time 
many things are still unknown. The key to understanding neurological 
disorders such as senile dementia, Parkinson’s and Alzheimer’s diseases 
may well lie in understanding the fundamental neurochemistry of 
metals such as iron, zinc, copper and manganese in the brain. These 
and many other basic questions being exciting, we should not restrain 
support and we must provide freedom for basic exploration studies, 
since they may unfold breakthroughs. In face of the outbreak of SARS-
CoV-2, the role of science has become even more evident, and its 
absolute necessity is clear. Let us celebrate science and new knowledge, 
and cheer for much more to come.
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